<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954603</url>
  </required_header>
  <id_info>
    <org_study_id>MedCMU Que vs Halo - 2008</org_study_id>
    <secondary_id>Que vs Halo - 2008</secondary_id>
    <nct_id>NCT00954603</nct_id>
  </id_info>
  <brief_title>A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium</brief_title>
  <acronym>QHdelirium</acronym>
  <official_title>Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether quetiapine, and haloperidol are effective
      and safe in the treatment psychiatric symptoms in patients with delirium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A delirious state often founds in general hospitals and remains a significant cause of death.
      Existing methods of treatment includes identification and elimination of factors contributing
      to the delirium in addition to pharmacological and nonpharmacological treatment interventions
      (Trzepacz et al., 1999). Antipsychotics can play an important role in the management of the
      symptoms of delirium.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    few delirious patients were enrolled.
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in delirium rating scale and clinical global improvement</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare extrapyramidal and other report side effects of quetiapine and haloperidol from modified Simpson Angus scale and other report side effects.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atypical antipsychotic drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>typical antipsychotic drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
    <description>25-100 mg</description>
    <arm_group_label>quetiapine</arm_group_label>
    <other_name>seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol</intervention_name>
    <description>0.5-2 mg</description>
    <arm_group_label>haloperidol</arm_group_label>
    <other_name>haldol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 -75 years

          -  Was admitted in Maharaj Nakhon Chiang Mai hospital

          -  Was diagnosed by the diagnostic criteria for DSM-IV-TR delirium due to a general
             medical condition or delirium due to multiple etiologies

          -  Delirious state (delirium) of the patients was confirmed by using name-assess
             confusion assessment method (CAM) and assessment of severity with delirium rating
             scale-revised-98 (DRS-R-98)

          -  Have a written consent from the legal representatives

        Exclusion Criteria:

          -  Was diagnosed substance withdrawal delirium

          -  Having a history drug allergy either from quetiapine or haloperidol

          -  Female patients who are pregnant or breastfeeding

          -  No written consent from the legal representatives

          -  Received other anti-psychotic drug before attend the study

          -  Being ill with renal or hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benchalak Maneeton, Assoc Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry,Faculty of Medicine, Chiang Mai university, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of psychiatry, faculty of medicine, Chiang Mai university</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://emedicine.medscape.com/article/288890-treatment</url>
    <description>treatment delirium</description>
  </link>
  <link>
    <url>http://www.icudelirium.org/</url>
    <description>treatment delirium</description>
  </link>
  <link>
    <url>http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=DeliriumPG_05-15-06</url>
    <description>treatment delirium</description>
  </link>
  <link>
    <url>http://www.cochrane.org/reviews/en/ab005594.html</url>
    <description>treatment delirium</description>
  </link>
  <results_reference>
    <citation>Maneeton B, Maneeton N, Srisurapanont M. An open-label study of quetiapine for delirium. J Med Assoc Thai. 2007 Oct;90(10):2158-63.</citation>
    <PMID>18041437</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2009</study_first_submitted>
  <study_first_submitted_qc>August 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2009</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Associate prof. Benchalak Maneeton</name_title>
    <organization>department of psychiatry, faculty of medicine, Chiang mai university, Thailand</organization>
  </responsible_party>
  <keyword>delirium rating scale</keyword>
  <keyword>clinical global improvement</keyword>
  <keyword>extrapyramidal side effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

